What is Organon's zetia — revenue?

Organon (OGN) reported zetia — revenue of $87M in Q1 2026.

How has Organon's zetia — revenue changed year-over-year?

Organon's zetia — revenue increased by 2.4% year-over-year, from $85M to $87M.

What is the long-term trend for Organon's zetia — revenue?

Over 4 years (2021 to 2025), Organon's zetia — revenue has grown at a -2.5% compound annual growth rate (CAGR), from $378M to $342M.

What does zetia — revenue mean?

This metric represents the total gross sales generated by the Zetia product line within the company's established medicines portfolio. It reflects the market demand and commercial performance of this specific pharmaceutical therapy over a given fiscal period. Monitoring this revenue stream helps investors assess the lifecycle stage and contribution of mature assets to the company's overall top-line results.

Organon OGN Zetia — Revenue

Other product segments

Nexplanon/Implanon NXT

$201M-19.0%

Other

$87M+11.5%

Atozet

$85M+10.4%

Other Non-Opiod Pain, Bone and Dermatology

$68M0.0%

Hadlima

$67M+42.6%

Nasonex

$65M-9.7%

Follistim AQ

$61M-11.6%

Arcoxia

$59M-4.8%

Cozaar/Hyzaar

$57M+3.6%

Renflexis

$57M0.0%

Emgality

$54M+68.8%

Other Women's Health

$46M+7.0%

Singulair

$40M-45.9%

Diprospan

$35M+16.7%

Dulera

$35M-18.6%

Clarinex

$31M-8.8%

Propecia

$30M+15.4%

Fosamax

$29M-12.1%

Other Cardiovascular

$28M-6.7%

Ganirelix Acetate Injection

$26M-3.7%

Marvelon/Mercilon

$26M-33.3%

Proscar

$26M+8.3%

Vtama

$25M+4.2%

NuvaRing

$24M+9.1%

Other Biosimilars

$24M—

Vytorin

$21M-8.7%

Brenzys

$20M+42.9%

Other Respiratory

$12M-7.7%

Rosuzet

$6M+50.0%

Jada

$5M-66.7%

Ontruzant

$5M-72.2%

Similar metrics at other companies

BMYZeposia — Total Revenues

$118M+10.3%

LLYVerzenio — Revenue

$1.3B+12.3%

LLYZepbound — Revenue

$4.16B+79.9%

JAZZZiihera — Revenue from Contract with Customer, Excluding Assessed Tax

$13.3M+565%

GILDYeztugo — Total revenues

$166M—

INCYZYNYZ — Total revenues

$41.39M+1,276%

Other financials

Income statement

See full

Revenue$1.5B-3.5%

Gross profit$783.0M-6.9%

Net income$146.0M+67.8%

EPS (diluted)$0.55+66.7%

Balance sheet

See full

Cash & equivalents$1.1B+104%

Total debt$8.6B-4.3%

Total equity$903.0M+66.6%

Total assets$13.0B-1.2%

Cash flow

See full

Operating cash flow$225.0M+200%

CapEx$37.0M+15.6%

Free cash flow$188.0M+337%

Valuation

See full

Market cap$3.53B-59.4%

Enterprise value$10.98B-26.4%

P/E6.6×+2.1×

P/S0.6×-0.8×

Profitability

See full

Gross margin52.8%-4.4pp

Net margin8%-12.3pp

FCF margin11.1%-1.3pp

Returns & leverage

See full

Return on equity71.6%—

Debt / equity9.5×-7.0×

Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's zetia — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Organon's zetia — revenue?: Organon (OGN) reported zetia — revenue of $87M in Q1 2026.
How has Organon's zetia — revenue changed year-over-year?: Organon's zetia — revenue increased by 2.4% year-over-year, from $85M to $87M.
What is the long-term trend for Organon's zetia — revenue?: Over 4 years (2021 to 2025), Organon's zetia — revenue has grown at a -2.5% compound annual growth rate (CAGR), from $378M to $342M.
What does zetia — revenue mean?: This metric represents the total gross sales generated by the Zetia product line within the company's established medicines portfolio. It reflects the market demand and commercial performance of this specific pharmaceutical therapy over a given fiscal period. Monitoring this revenue stream helps investors assess the lifecycle stage and contribution of mature assets to the company's overall top-line results.